Clinical Trial

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2022 (before its estimated August 9, 2024 completion). Its status may not reflect the trial's current state.
Summary
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-16
Trial Details
NCT Number NCT05436223
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: Shanghai Zhongshan Hospital
Conditions B-cell Non-Hodgkin's Lymphoma
Enrollment 100 participants
Start Date 2021-08-09
Primary Completion 2024-08-09 (estimated)
Study Completion 2026-08-09 (estimated)
Updated on ClinicalTrials.gov 2022-07-05